Regeneron Pharmaceuticals Inc vs Valero Energy Corporation — how do they compare? Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B), while Valero Energy Corporation trades at $434.85 (market cap $127.78B). The key difference: Valero Energy Corporation is the larger of the two by market cap, and Valero Energy Corporation pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Valero Energy Corporation for 56 Days on average.
| REGN | VLO | |
|---|---|---|
Market Cap | $76.14B | $127.78B |
Volume | 500,239 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $852.03 | $443.80 |
52-Week Low | $557.73 | $156.39 |
Typical Hold Time | 107 Days | 56 Days |
Enterprise Value | $70.85B | $131.26B |
Dividend Yield | 0.51% | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Valero Energy (VLO) trades at $433.75, up 2.28% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages, though RSI levels suggest overbought conditions. Fundamentally, VLO has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $20.17 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%. The company maintains a solid balance sheet with a debt-to-asset ratio of 18.31% as of 2024.
VLO's outlook is supported by robust refining margins and a favorable analyst consensus, with 54% buy ratings and a $408.10 price target. Key risks include potential diesel export bans and volatile energy markets. Investors should weigh strong cash flow projections against cyclical industry headwinds for balanced exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →